Symbols

NMRA

Neumora·NASDAQ

--(--)

Signals Analysis

Bullish signal 2

Bearish signal 0

Consensus Rating "Strong Buy"

Ample Liquidity

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About NMRA

Neumora Therapeutics, Inc.

A biopharmaceutical company that develops drugs for brain diseases

Industry

Pharmaceutical

Established Date

Listing Date

09/15/2023

Exchange

NASDAQ Stock Exchange

Full-time Employees

110

Fiscal Year Ends

12-31

Website

www.neumoratx.com

Security Type

Common stock

Office address

490 Arsenal Way, Suite 200, Watertown, Massachusetts 02472

Business

Introduction

Neumora Therapeutics, Inc., was founded in November 2019 as a Delaware corporation under the name RBNC Therapeutics, Inc. The company changed its name to Neumora Therapeutics, Inc., in October 2021. The company is a clinical-stage biopharmaceutical company that takes a fundamentally different approach to the treatment of brain diseases in response to the global brain disease crisis. The company's rapidly expanding therapeutic pipeline now includes seven clinical and preclinical neuroscience programs targeting a wide range of underserved neuropsychiatric and neurodegenerative diseases with new mechanisms of action. The company's most advanced product candidate, navacaprant (NMRA-140), is a new once-daily oral kappa opioid receptor (KOR) antagonist being developed for the treatment of major depression disorder (MDD), which the company believes has the potential to provide significant advantages over standard of care if approved.

Earnings Call

Q1/2025

Estimate EPS-0.38

Actual EPS-0.42

Estimate Revenue--

Actual Revenue0

Neumora Therapeutics Q1 2025: Unraveling Contradictions in KOASTAL Trials and Patient Selection Strategies

May 20,2025 08:21·
Earnings Decrypt

Q2/2025

Estimate EPS-0.37

Actual EPS-0.33

Estimate Revenue--

Actual Revenue0

Neumora's Q2 2025 Earnings Call: Unpacking Key Contradictions in M4 PAM Safety, Obesity Focus, and KOASTAL Studies

Aug 11,2025 08:21·
Earnings Decrypt

Company Financials

EPS

NMRA has released its 2025 Q3 earnings. EPS was reported at -0.35, versus the expected -0.34, missing expectations. The chart below visualizes how NMRA has performed over recent quarters, highlighting trends in earnings surprises.